Skip to content

US · KPTI · BIOTECHNOLOGY

Karyopharm Therapeutics Inc. (KPTI) intrinsic value and stock valuation

$0.02as of 2026-11-21 · Mkt cap 43.29M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Karyopharm Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values KPTI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KPTI’s statements →

Karyopharm Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Newton, MA 02459-3298 karyopharm.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$146.1M+6.2% 5y CAGRd
20112025
Net income
-$-196.04M
20112025
Free cash flow
-$-75.37M
20112025
Total equity
-$-292.93M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$146.1M$145.2M$146M$157.1M$209.8M
Operating income-$-90.71M-$-119.44M-$-129.54M-$-142.2M-$-98.27M
Net income-$-196.04M-$-76.42M-$-143.1M-$-165.29M-$-124.09M
EPSd-$-17.92M-$-9.41M-$-18.8M-$-30.27M-$-24.77M
Operating cash flow-$-75.37M-$-127.49M-$-92.72M-$-149.55M-$-107.12M
Capital expenditure$0.00-$-140K$0.00-$-120K-$-5.71M
Free cash flow-$-75.37M-$-127.63M-$-92.72M-$-149.67M-$-112.83M
Total assets$108.4M$164.4M$240.4M$358.2M$305.3M
Total debt$233.6M$194.5M$177M$179.1M$180.6M
Net debt$173.1M$132.1M$124.8M$43.9M-$-9.88M
Total equity-$-292.93M-$-186.02M-$-136.21M-$-16.66M-$-79.67M
Cash and short-term investments$63.7M$108.7M$191.4M$278M$228.6M
Income statement
20252024202320222021
Revenue$146.1M$145.2M$146M$157.1M$209.8M
Cost of revenue$5.95M$6.01M$4.94M$5.21M$3.4M
Gross profit$140.1M$139.2M$141.1M$151.9M$206.4M
Research and development expenses$125.6M$143.2M$138.8M$148.7M$160.8M
Selling, general and administrative expenses$105.2M$115.4M$131.9M$145.4M$143.9M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$230.8M$258.7M$270.6M$294.1M$304.7M
Cost and expenses$236.8M$264.7M$275.6M$299.3M$308.1M
Interest income$2.77M$7.4M$10.9M$2.36M$580K
Interest expense$45.9M$37.4M$23.8M$25M$26.1M
Depreciation and amortization$300K$340K$530K$620K$790K
Ebitda-$-149.85M-$-38.6M-$-118.42M-$-139.31M-$-96.98M
Operating income-$-90.71M-$-119.44M-$-129.54M-$-142.2M-$-98.27M
Total other income/expenses, net-$-105.29M$43.1M-$-13.24M-$-22.72M-$-25.55M
Income before tax-$-196M-$-76.36M-$-142.78M-$-164.92M-$-123.82M
Income tax expense$40K$60K$320K$370K$270K
Net income-$-196.04M-$-76.42M-$-143.1M-$-165.29M-$-124.09M
Weighted average shares outstanding$10.9M$8.12M$7.61M$5.46M$5.01M
Weighted average diluted shares outstanding$10.9M$8.12M$7.61M$5.46M$5.01M
Balance sheet
20252024202320222021
Cash and short-term investments$63.7M$108.7M$191.4M$278M$228.6M
Net receivables$26.2M$30.8M$27M$47.1M$22.5M
Inventory$4.04M$4.74M$3.04M$4.22M$4.11M
Total current assets$103.2M$156.5M$233.9M$350.2M$275.6M
Property, plant and equipment, net$4.65M$6.28M$4.88M$7.38M$9.56M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$350K$0.00$0.00$0.00$0.00
Total non-current assets$5.27M$7.93M$6.52M$8.01M$29.7M
Total assets$108.4M$164.4M$240.4M$358.2M$305.3M
Accounts payable$4M$5.11M$3.12M$2.77M$1.6M
Short-term debt$22M$24.9M$3.31M$2.87M$2.32M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$92.1M$92.3M$69.5M$65.9M$73.7M
Long-term debt$211.6M$169.7M$173.7M$176.2M$178.3M
Deferred revenue, non-current$72.3M$0.00$0.00$0.00$0.00
Total non-current liabilities$309.3M$258.2M$307.2M$308.9M$311.3M
Capital lease obligations$6.71M$7.15M$6.1M$8.97M$11.3M
Total liabilities$401.3M$350.4M$376.6M$374.8M$385M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.76B-$-1.56B-$-1.49B-$-1.34B-$-1.18B
Accumulated other comprehensive income (loss)$70K-$-360K-$-160K-$-640K$190K
Total equity-$-292.93M-$-186.02M-$-136.21M-$-16.66M-$-79.67M
Total investments$3.56M$46.2M$139.2M$142.8M$38.2M
Total debt$233.6M$194.5M$177M$179.1M$180.6M
Net debt$173.1M$132.1M$124.8M$43.9M-$-9.88M
Cash flow statement
20252024202320222021
Net income-$-196.04M-$-76.42M-$-143.1M-$-165.29M-$-124.09M
Depreciation and amortization-$-110K$340K$530K$620K$790K
Stock-based compensation$14.1M$18.4M$21.7M$35.4M$29.8M
Change in working capital$28.3M-$-300K$31.4M-$-19.99M-$-23.19M
Accounts receivable$4.59M-$-3.8M$20.1M-$-5.08M-$-9.62M
Inventory$700K-$-1.7M$1.18M-$-120K-$-1.46M
Accounts payable-$-1.1M$1.98M$350K$1.17M-$-2.85M
Net cash provided by operating activities-$-75.37M-$-127.49M-$-92.72M-$-149.55M-$-107.12M
Investments in property, plant and equipment$0.00-$-140K$0.00-$-120K-$-5.71M
Acquisitions, net$0.00$0.00$0.00$104.3M$5.5M
Net cash used for investing activities$43.4M$95.5M$7.94M-$-104.26M$141.8M
Common stock issued$9.51M$1.45M$1.12M$189.8M$9.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$30.1M$41.7M$1.12M$193.7M$73.7M
Net change in cash-$-1.92M$9.62M-$-83.69M-$-60.56M$108.3M
Cash at end of period$60.9M$62.8M$53.2M$136.9M$197.4M
Operating cash flow-$-75.37M-$-127.49M-$-92.72M-$-149.55M-$-107.12M
Capital expenditure$0.00-$-140K$0.00-$-120K-$-5.71M
Free cash flow-$-75.37M-$-127.63M-$-92.72M-$-149.67M-$-112.83M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Karyopharm Therapeutics Inc.

        Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

        CEO
        Richard A. Paulson
        Employees
        228
        Beta
        0.94

        Explore

        Frequently asked questions

        What is the intrinsic value of Karyopharm Therapeutics Inc. (KPTI)?

        InvestorsCraft does not currently publish an intrinsic value for KPTI. How the IC value is calculated.

        Is KPTI undervalued?

        InvestorsCraft does not publish an undervaluation signal for KPTI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.